Test Price
2,800 AED✅ Home Collection Available
NGF Gene HSAN5 Next-Generation Sequencing (NGS) Genetic Test in UAE
Executive Summary & Core Metrics
This DHA-licensed Next-Generation Sequencing (NGS) test analyzes the entire NGF gene to detect pathogenic variants causing Hereditary Sensory and Autonomic Neuropathy Type 5 (HSAN5). The assay delivers 99.9% diagnostic sensitivity through an ISO 9001:2015 accredited molecular genetics laboratory (Cert: INT/EGQ/2509DA/3139) and is overseen by Consultant Medical Geneticist Lina Osama Zaki Quteineh (DHA Registration ID: 9294403).
- ✓Diagnostic Accuracy: 99.9% sensitivity and specificity via Illumina® NGS platform with orthogonal Sanger confirmation of all clinically relevant variants.
- ✓Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM across Dubai, Abu Dhabi, Sharjah, and all Northern Emirates.
- ✓Clinical Guidance: Complimentary post-test telephonic consultation with a DHA-licensed genetics specialist to interpret results and outline management steps.
- ✓Insurance & Billing: Direct billing verification via WhatsApp +971 54 548 8731; cash, card, and all major insurance plans accepted.
Test Overview & Methodology
This comprehensive NGS assay provides complete coverage of the NGF gene, including all coding exons, exon-intron boundaries, deep intronic regions, and upstream regulatory elements. The test detects single nucleotide variants, small insertions and deletions (indels), and copy number variants (CNVs). All pathogenic and likely pathogenic findings are confirmed by Sanger sequencing to ensure 100% analytical validity before clinical reporting.
| Feature | NGF NGS Test (DNA Labs UAE) | Single-Gene Sanger Sequencing |
|---|---|---|
| Variant Detection Scope | Full gene coverage: coding exons, deep intronic regions, 5'/3' UTR, CNVs, and mosaic variants at ≥5% allele frequency | Targeted coding exons only; large deletions, duplications, and deep intronic variants routinely missed |
| Analytical Platform | Illumina® NGS (paired-end 150 bp) with orthogonal Sanger confirmation of all reportable variants | Sanger dideoxy terminator sequencing of PCR-amplified coding exons |
| Turnaround Time | 21–28 calendar days; expedited family variant testing available within 10 business days | 28–42 calendar days; no expedited option for familial testing |
Physician Insight & Safety Protocols
"The NGF genetic test provides a definitive molecular diagnosis for individuals with congenital insensitivity to pain and suspected HSAN5. However, a negative NGS result does not exclude all hereditary sensory and autonomic neuropathies; additional genes such as NTRK1, SCN9A, and WNK1 may warrant investigation. All results must be correlated with a detailed neurological examination, autonomic function testing, and three-generation family pedigree. Post-test genetic counselling is strongly recommended to discuss recurrence risks, cascade testing for at-risk relatives, and implications for family planning."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Patient Safety Advisory
Medication & Clinical Management Guidance
Patients currently taking analgesic, anticonvulsant, or antihypertensive medications should continue their prescribed regimen unless explicitly directed by their treating physician. The NGF genetic test is a diagnostic aid and does not replace ongoing neurological or multidisciplinary care. Individuals with HSAN5 require regular podiatric, dermatologic, and orthopedic surveillance to prevent complications from unrecognized injuries.
Exclusion Criteria & Emergency Red Flags
- Blood transfusion or hematopoietic stem cell transplant within the preceding 14 days may cause false-negative results due to recipient-donor chimerism.
- Inability to provide informed consent or absence of a legally authorized guardian for minor patients (compliance with Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Current anticoagulation therapy without prior medical clearance for venipuncture; an alternative dried blood spot (FTA card) specimen may be accepted following clinical risk assessment.
Seek immediate medical attention for: new-onset thermal insensitivity leading to burns or skin ulceration, unexplained fractures or joint deformities, or severe postural hypotension with recurrent syncope.
Patient FAQ & Clinical Guidance
1. What is the NGF gene HSAN5 test, and why is it needed?
This NGS-based test detects pathogenic variants in the NGF gene that cause Hereditary Sensory and Autonomic Neuropathy Type 5, a rare autosomal recessive disorder characterized by profound congenital insensitivity to pain, anhidrosis, and autonomic dysfunction. Molecular confirmation is essential for accurate genetic counselling, prenatal planning, and personalized surveillance protocols to prevent injury and complication.
2. How is the sample collected, and do I need to prepare?
A standard venipuncture of 3–5 mL of peripheral whole blood in an EDTA tube is required. No fasting, dietary modification, or medication adjustment is needed. Our DHA-licensed mobile phlebotomist will visit your home, hotel, or office between 8 AM and 11 PM, adhering to strict cold-chain transport protocols. For patients with difficult venous access, an alternative FTA card dried blood spot collection is available.
3. When will I receive my results, and how will they be explained?
Clinical reports are issued within 21–28 calendar days from sample receipt. Each report is reviewed and co-signed by a Consultant Medical Geneticist (DHA-licensed) and includes variant interpretation according to ACMG/AMP guidelines, a clear statement of pathogenicity, and actionable clinical recommendations. A complimentary telephonic consultation is provided to explain findings and coordinate follow-up care with your neurologist or genetic counsellor.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under the regulatory oversight of the Dubai Health Authority (DHA Facility License Number: 1143). All genetic data obtained from this NGS assay is processed, stored, and transmitted in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent, clinical safety, and medical liability protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. No genetic information is shared with third parties without explicit written authorization from the patient or legal guardian.
Clinical & Logistical Metadata
| Test Name | NGF Gene HSAN5 Next-Generation Sequencing (NGS) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 21–28 calendar days (expedited familial testing available within 10 business days) |
| Sample Type / Matrix | Peripheral whole blood (EDTA, 3–5 mL) or FTA card dried blood spot; VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (daily 8 AM – 11 PM) |
| Methodology Used | Next-Generation Sequencing (Illumina® paired-end 150 bp) with orthogonal Sanger confirmation of all clinically reportable variants; CNV analysis via read-depth algorithms |
| ICD-10-CM Code | G60.8, Z13.7 (Other hereditary and idiopathic neuropathies; encounter for genetic susceptibility screening) |
| LOINC Code | 81307-7 (NGF gene full mutation analysis in Blood or Tissue by NGS) |
| DHA Facility License & Laboratory Address | DHA License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians